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Abstract 
Water-in-mineral oil adjuvants induce a strong long-term humoral immune response and are widely used in poultry 
vaccines. New adjuvants that also increase the cellular immune response could help to extend the vaccinal cross-
protection against different viral strains or serotypes. We have developed a new water-in-oil adjuvant, MontanideTM
ISA 71 VG, based on a specific enriched light mineral oil which stimulates both humoral and cellular immune 
responses. Here, using a Newcastle Disease vaccine model, we demonstrate that this new adjuvant is safe, can 
improve vaccine efficacy in poultry and could allow the reduction of injection doses of inactivated poultry vaccines. 
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Keywords: Adjuvant; Cell mediated immunity; Newcastle disease; Poultry vaccine; Montanide 
1. Introduction 
Water-in-mineral oil (W/O) emulsion adjuvants are extensively used for inactivated avian vaccines 
formulation. These adjuvants are indeed strong adjuvants that induce long-term efficacy in poultry 
vaccines. However, it should be noted that a specific care has to be given to the quality of surfactants as 
well as the nature of the oil to avoid safety issues [1]. Whereas W/O adjuvants have mostly been used to 
increase humoral immune response, new adjuvants that also increase the cellular immune response could 
improve the efficacy of avian vaccines. For example, they could help to extend the vaccinal cross-
protection against different viral strains or serotypes. 
The MontanideTM water-in-oil range of adjuvants has been shown to be safe and efficient in diverse 
poultry disease models [2]. Montanide ) is a mineral oil based adjuvant that has 
been developed for the manufacture of water-in-mineral oil emulsions. ISA 71 is composed of an 
enriched light mineral oil able to stimulate both humoral and cellular immune response, with an 
extremely refined emulsifier obtained from mannitol and purified oleic acid of vegetable origin. This 
adjuvant was specifically formulated to stimulate cell-mediated immunity, and has been shown previously 
to induce strong humoral and cellular immune response in subunit vaccines for chickens [3,4,5]. 
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Newcastle disease (ND) is an acute viral disease of domestic poultry and other bird species, which 
presents primarily as a respiratory disease and is endemic in many countries. It is a worldwide problem 
for which clinical manifestations vary from high mortality to asymptomatic infections. Newcastle disease 
is caused by an RNA virus, Newcastle disease virus (NDV, also called avian paramyxovirus-1) from the 
Paramyxoviridae family [6].  
 
Different NDV strains exist but are antigenically considered to all belong to the same serotype. It is 
widely thought that a ND vaccine made with any NDV strain induces protection against morbidity and 
mortality from any virulent NDV strain challenge. However it has been shown that when the vaccine and 
challenge strains were phylogenetically close, the protection from infection induced by the vaccine was 
improved [7]. As increasing cell mediated immune response (CMI) may increase cross-protection 
between different strains, it could increase the efficacy of the vaccine, especially when different NDV 
variants such as local strains are present on the field. 
 
In this study, we show that the CMI adjuvant MontanideTM ISA 71 VG is a safe adjuvant and can 
improve the protection conferred by ND vaccines in chickens. Compared to a standard formulation, such 
an adjuvant can also allow the injection of reduced vaccine doses to confer protection to the animals.  
2. Materials and Methods 
Two similar studies were conducted in parallel with respectively 1 day old and 8 days old chickens 
(Tables 1 and 2). 
2.1. Vaccine groups  
1 day old and 8 days old chickens were respectively separated in 4 different vaccine groups: 
  
 Group 1: ISA 71 adjuvanted ND vaccine (1ml) 
 Group 2: Standard W/O adjuvanted ND vaccine (1ml)  
 Group 3: Commercial ND vaccine (2ml) 
 Group 4: Not vaccinated.  
 
Both experimental vaccines (groups 1 and 2) contained the same amount of the same antigen 
(Inactivated NDV). They were prepared by high shear mixing of the antigenic phase with the adjuvant. 
ISA 71 is used at 70% (w/w) in the vaccine. Another commercial inactivated ND formulation was 
included as a positive control.  
 
In each group, 40 chickens were vaccinated at D0 by intramuscular injection of the corresponding 
vaccine. Negative control groups were not vaccinated.  
Table 1. 1 day old chickens: Vaccination groups 
 
 
Groups Adjuvant Injected Dose Number of chickens 
1- ISA 71VG_1 W/O: MontanideTM ISA 71 VG 0.1ml 40 (1 day old) 
2- Tween/Span_1 W/O: Tween/Span + mineral oil 0.1ml 40 (1 day old) 
3- Commercial_1 W/O: Undisclosed 0.2ml 40 (1 day old) 
4- Control_1 / / 40 (1 day old) 
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Table 2. 8 days old chickens: Vaccination groups 
 
2.2. Safety assessment  
The safety of the vaccines was assessed by observation of general behavior of the animals and of the 
injection site after vaccination. 
2.3. Efficacy assessment  
20 chickens of each group were challenged at 28 days post vaccination by intramuscular injection of a 
ND velogenic strain from southern India (Intracerebral pathogenicity index = 2) at a dose of 105 EICD per 
bird. Challenged chickens were observed for 14 days post challenge for the apparition of clinical signs.  
Protection was expressed as the percentage of live and healthy animals at 14 days post challenge. 
 
20 birds in each group were not challenged and kept until 49 days post vaccination for blood sampling. 
Blood samples were taken from non-challenged chickens at D14, 21, 28, 35, 42 and 49 post vaccination 
for antibody titration. Antibody titers were measured using haemagglutination inhibition (HI) technique. 
2.4.  Statistical analysis 
Statistical analysis of the results was performed by ANOVA analysis (P<0.05). 
3. Results 
3.1. Safety results 
No modification of animal behavior could be noticed in any group. The injection sites were checked 
after injection during the trial. No local reactions were observed. 
3.2. Efficacy results: Antibody titers 
When 1 day old chickens were vaccinated, antibody levels were significantly higher at days 21, 42 and 
49 after vaccination in the group vaccinated with the ISA 71 adjuvanted vaccine than in all groups 
vaccinated with other W/O formulas (Fig. 1a). In the ISA 71 group, antibody titers were still rising at D49 
post injection.  
 
When 8 days old chickens were vaccinated, antibody titers were significantly higher at days 14 and 
days 21 post vaccination in the ISA 71 group than in all other groups (Fig. 1b).  
 
Both short term and long term antibody production was increased by the use of cell-mediated immunity 
adjuvant ISA 71 for 1 day old chickens vaccination. In the case of 8 days old birds, short term antibody 
production was increased by the use of ISA 71. 
Groups Adjuvant Injected Dose Number of chickens 
1- ISA 71VG_8 W/O: MontanideTM ISA 71 VG 0.1ml 40 (8 days old) 
2- Tween/Span_8 W/O: Tween/Span + mineral oil 0.1ml 40 (8 days old) 
3- Commercial_8 W/O: Undisclosed 0.2ml 40 (8 days old) 
4- Control_8 / / 40 (8 days old) 
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Fig. 1. (a) Antibody titers (HI) measured in 1 day old chickens (20 chickens/group); (b) Antibody titers (HI) measured in  8 days old 
chickens (20 chickens/group). Data is presented as mean ± s.e.m. 
3.3. Efficacy assessment: Protection  against virulent  challenge 
A virulent challenge procedure was performed at day 28 post injection for 20 chickens per group. 
Protection is expressed as the percentage of live and healthy animals at 14 days post challenge. According 
to Indian pharmacopeia at least 90% of protection is required for efficient vaccination against ND. 
 
At D28 post vaccination, 1 day old chickens were protected above 90% by the ISA 71 formula (Table 
3). 8 days old chickens were protected above 90% by the Tween/Span formula and the ISA 71 formula, 
which was 100% protective (Table 4). The ISA 71 formulation was the only vaccine able to reach 
accepted protective levels both in 1day old and 8 days old chickens. Interestingly, the commercial vaccine 
induced only 70% of protection in 1 day old chickens, and 55% of protection in 8 days old chicken in this 
trial. 
 
It should be noted that the challenge procedure was performed at 28 days post injection, when no 
significant antibody titers differences could be observed between groups adjuvanted with ISA 71 or with 
regular W/O adjuvant, both in 1 day old and 8 days old chickens. At 28 days post vaccination, both 
formulas induced high antibody titers. The comparison of antibody levels and challenge results therefore 
suggests that the ISA 71 based vaccine should be protective on a longer time period compared to standard 
formulation, and up to at least 49 days post vaccination in 1 day old chickens. 
Table 3. 1 day old chickens: Protection to challenge (28 days post vaccination) 
 
Groups (1 day old) 
Number of healthy 
chickens at 14 days 
post challenge 
Total number of 
challenged chickens % Protection 
ISA 71VG_1 18 20 90% 
Tween/Span_1 17 20 85% 
Commercial _1 14 20 70% 
Control_1 1 20 5% 
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Table 4. 8 days old chickens: Protection to challenge (28 days post vaccination) 
4. Discussion 
Safe water in oil emulsion adjuvants are required for the formulation of efficient inactivated poultry 
vaccines. Benefits expected from the use of oil adjuvants include the enhancement of the amplitude of 
short term immune response and the extension of the longevity of the protection given by the vaccine. 
Adjuvants can also be added to reduce the injected vaccine dose, the number of required immunizations 
or the antigenic load in the vaccine. 
 
 Another role of vaccine adjuvants is to modulate the type of immune response induced by the antigen, 
for example by enhancing the cell mediated immunity conferred by the vaccine. The novel adjuvant 
MontanideTM ISA 71 VG is an efficient ready-to-use adjuvant based on a specific mineral oil that has 
been shown to stimulate cell mediated immune response in chicken [3,4]. 
 
Whereas 0.3 to 0.5ml doses are routinely used for standard ND vaccines, we could show in this study 
that the injection of 0.1ml of ISA 71 adjuvanted vaccine was sufficient to induce full protection of 8 days 
old and 1 day old chickens at D28 and high antibody titers up to the end of the trial at D49. Compared to 
standard water in oil formulation, ISA 71 induced higher short term antibody titers, and longer protection 
for 1 day old chickens. 
 
Surprisingly, even with the injection of a 0.2ml dose, the commercial vaccine tested in the study did not 
induce an acceptable protection level. This may be linked to the NDV strain used in this vaccine that may 
not be adapted to the velogenic Indian strain applied during the challenge.  
 
Finally, we could demonstrate that MontanideTM ISA 71 VG is able to trigger a protective immune 
response in a Newcastle disease model. These results indicate that MontanideTM ISA 71 VG is an efficient 
adjuvant for poultry vaccine formulation, and that such an adjuvant can allow the reduction of poultry 
vaccines injection dose that is required to induce protection in chickens. 
 
Groups (8 days old) 
Number of healthy 
chickens at 14 days 
post challenge 
Total number of 
challenged chickens % Protection 
ISA 71VG_8 20 20 100% 
Tween/Span_8 19 20 95% 
Commercial _8 11 20 55% 
Control_8 0 20 0% 
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